Latest News on TMO

Financial News Based On Company


Advertisement
Advertisement

Thermo Fisher Scientific (TMO) Stock Looks Priced At A Premium To Fair Value

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-stock-looks-priced-at-a-premium
Thermo Fisher Scientific (TMO) appears to be priced at a premium to its fair value based on a Discounted Cash Flow (DCF) model, with its current share price of $688.75 significantly above the DCF estimate. While new product launches and its strong position in life sciences markets contribute to market optimism, the valuation suggests investors are paying extra for its growth potential. Analyst narratives offer both bull and bear cases, highlighting the importance of future execution and sustained earnings growth to justify the current stock price.

Thermo Fisher (TMO) Up 1.8% Since Last Earnings Report: Can It Continue?

https://ca.finance.yahoo.com/news/thermo-fisher-tmo-1-8-153011157.html
Thermo Fisher Scientific (TMO) shares have increased by 1.8% since its last earnings report, outperforming the S&P 500. The company reported strong Q3 2026 results with adjusted earnings of $6.68 per share and revenues of $12.14 billion, both exceeding analyst estimates. Despite strong financial performance and expanding operating margins across most segments, the stock currently holds a Zacks Rank #3 (Hold) due to downward revisions in estimates.

Introducing the CellularAI algorithm: Predicting single-cell responses to genetic perturbations

https://www.illumina.com/science/genomics-research/articles/introducing-the-cellularai-algorithm--predicting-single-cell-res.html
Illumina's BioInsight AI Lab has announced CellularAI, an open-source algorithm designed to predict transcriptome-wide responses to genetic perturbations in previously unseen cell types. This algorithm, which won the Arc Institute’s Virtual Cell Challenge, aims to improve the accuracy of biological predictions by leveraging extensive perturbation data. CellularAI integrates with Illumina's single-cell research solutions to observe, predict, and test cellular responses, offering a transparent framework for researchers.

Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer

https://www.pfizer.com/news/articles/learning_at_the_rate_of_evidence_how_ai_is_reshaping_r_d_at_pfizer
Pfizer is transforming its R&D operations by integrating AI across the entire drug development process, from discovery to pharmacovigilance. The ambitious goal is to halve the time from idea to first-in-human trials and then halve the time to approval by leveraging petabytes of proprietary data and AI models like FLOWR for molecule design and GENESIS for safety monitoring. This initiative aims to accelerate decision-making, enhance scientific judgment, and ultimately deliver breakthroughs to patients faster, all while maintaining rigorous trust, privacy, and regulatory standards.

Thermo Fisher Scientific Sees Faster 2027 Growth as Biotech Spending Recovers

https://www.tradingview.com/news/marketbeat:ed84ca6aa094b:0-thermo-fisher-scientific-sees-faster-2027-growth-as-biotech-spending-recovers/
Thermo Fisher Scientific expects its growth to strengthen to approximately 5% in the second half of 2026 and continue improving in 2027, driven by a recovery in biotechnology spending and stabilization in academic research. CEO Marc Casper highlighted potential benefits from U.S. manufacturing reshoring, artificial intelligence, and growth in China supporting a 7% growth objective by 2028. The company is seeing increased demand for lab supplies and strong performance in pharma services, with AI being applied to enhance R&D for customers.
Advertisement

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

https://www.biospace.com/press-releases/thermo-fisher-scientific-launches-gibco-vaxevo-cd-293-medium-to-advance-adenovirus-vaccine-production
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium. This medium is designed to support robust HEK293 cell growth and high-titer adenovirus production, simplifying suspension-based workflows for vaccine developers. It aims to enhance manufacturing readiness and productivity for human and animal health adenovirus vaccine production.

Should Vaccine Medium Launch Require Action From Thermo Fisher Scientific (TMO) Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/should-vaccine-medium-launch-require-action-from-thermo-fish
Thermo Fisher Scientific recently launched Gibco VaxEvo CD 293 Medium, a new solution for adenovirus vaccine production. While this product supports the company's focus on pharma and biotech customers and bioproduction, analysts view it as an incremental development rather than a major factor for near-term results. The company's investment narrative continues to depend on the recovery of funding-sensitive customers and effective portfolio reshaping, alongside its consistent dividend payouts and strategic M&A activities.

Unitedhealth Group Inc Stock (UNH) Moved Down by 4.61% on Nov 18: Key Drivers Unveiled

https://www.tradingkey.com/news/market-movers/262311282-market-movers-unh-20261118
UnitedHealth Group Inc. (UNH) experienced a 4.61% drop in stock price due to intensified regulatory scrutiny, particularly proposed federal oversight initiatives from the Centers for Medicare and Medicaid Services (CMS) aiming to curb healthcare waste and expand risk-adjustment audits, which could lead to significant retroactive recoveries. Additionally, renewed political scrutiny on vertical integration in healthcare, especially concerning health insurers controlling pharmacy benefit managers and providers, added to operational risk. Persistent industry-wide operational pressures like elevated medical utilization and compressed underwriting spreads further dampened market sentiment.

Thermo Fisher Scientific Introduces Gibco VaxEvo CD 293 Medium for Adenovirus Vaccine Production

https://biopharmaapac.com/news/18/8697/thermo-fisher-scientific-introduces-gibco-vaxevo-cd-293-medium-for-adenovirus-vaccine-production.html
Thermo Fisher Scientific has launched Gibco VaxEvo CD 293 Medium, a new chemically defined and animal origin-free medium for suspension HEK293 cell culture. This product aims to support high-titer adenovirus vaccine production, helping developers from early process development through manufacturing. Benchmarking studies showed the medium supported adenovirus type 5 (Ad5) titers comparable to, and in some cases significantly higher than, other supplier media.

Thermo Fisher introduces VaxEvo medium for adenovirus vaccines

https://www.biospectrumasia.com/news/35/28703/thermo-fisher-introduces-vaxevo-medium-for-adenovirus-vaccines.html
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined medium for developers of adenovirus-based vaccines. This animal-component-free medium supports HEK293 cell growth in suspension and aims to simplify vaccine production from early development through scale-up. Benchmarking studies showed the medium supported adenovirus type 5 titres comparable to, and in some cases significantly higher than, selected commercial media.
Advertisement

If You Invested $100 In Thermo Fisher Scientific Stock 10 Years Ago, You Would Have This Much Today

https://www.benzinga.com/news/26/11/63384954/if-you-invested-100-thermo-fisher-scientific-stock-10-years-ago-you-would-have-much-today
This article calculates the return on a $100 investment in Thermo Fisher Scientific (NYSE: TMO) made 10 years ago. It reveals that such an investment would now be worth $466.70 due to the company's annualized return of 16.91%, outperforming the market by 4.14%. The piece highlights the significant impact of compounded returns over time.

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

https://finance.yahoo.com/healthcare/articles/thermo-fisher-scientific-launches-gibco-133000524.html
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium designed to improve suspension HEK293 cell growth and adenovirus vaccine production. This medium aims to simplify suspension-based workflows from process development to scalable manufacturing. Benchmarking studies showed it supported adenovirus type 5 titers comparable to or up to 5.7-fold higher than other media, without needing a dedicated feed.

Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium to Advance Adenovirus Vaccine Production

https://www.streetinsider.com/Business+Wire/Thermo+Fisher+Scientific+Launches+Gibco%E2%84%A2+VaxEvo%E2%84%A2+CD+293+Medium+to+Advance+Adenovirus+Vaccine+Production/27367292.html
Thermo Fisher Scientific has launched Gibco™ VaxEvo™ CD 293 Medium, a new chemically defined and animal origin-free cell culture medium. This product is designed to enhance suspension HEK293 cell growth and high-titer adenovirus production, crucial for vaccine development and manufacturing. It aims to simplify upstream workflows and improve productivity for human and animal health vaccine developers.

Focused Ion Beam Market Companies, Size & Trends 2026-2035

https://www.precedenceresearch.com/focused-ion-beam-market
The global focused ion beam (FIB) market, valued at USD 1.45 billion in 2026, is projected to reach USD 3.00 billion by 2035, growing at a CAGR of 8.4%. This growth is primarily driven by the increasing complexity of semiconductor devices, advanced packaging, and demand in materials science and life sciences, particularly for cryo-electron tomography. Asia Pacific leads the market and is expected to remain the fastest-growing region.

Danaher Targets Faster Growth With Acquisitions, AI and a Diagnostics Push

https://www.newsbreak.com/marketbeat-318743589/5014123923810-danaher-targets-faster-growth-with-acquisitions-ai-and-a-diagnostics-push
Danaher (NYSE:DHR) is pursuing accelerated core growth and market-share expansion through a focus on commercial execution, innovation, and strategic acquisitions, according to company leader Julie. The company is directing its substantial annual innovation budget toward high-growth opportunities, leveraging AI for increased productivity, and seeing significant opportunities in diagnostics and bioprocessing. Acquisitions remain a top priority, with over $11 billion deployed this year, expected to yield strong returns.
Advertisement

2026 PacBio SMRT Grant offers PCR free sequencing opportunity, Pacific Biosciences of California announces

https://tradersunion.com/news/companies/show/4294496-pacbio-sequencing-grant-2026/
Pacific Biosciences of California has launched its 2026 PacBio SMRT Grant, inviting researchers to apply for a project using PCR-free targeted HiFi sequencing technology. This initiative will fund 24 to 96 sample projects, aiming to advance research into complex genomic regions using the company's PureTarget sequencing method. Additionally, PacBio previously offered the 2026 PacBio Fiber-seq SMRT Grant for plant and animal research, reinforcing its commitment to expanding access to advanced sequencing technologies.

GxP Compliance in Life Sciences Is Non-Negotiable: SAP Is Raising the Standard

https://news.sap.com/2026/11/gxp-compliance-life-sciences-sap-raising-standard/
SAP is committed to raising GxP compliance standards in the life sciences sector by offering a GxP-ready public cloud ERP solution. This solution integrates GxP readiness into its core, covering applications, cloud operations, implementation tools, and data centers to ensure data integrity, auditability, and validation rigor. This initiative extends SAP's long-standing GxP readiness from private to public cloud, enabling life sciences companies to leverage advanced technologies like AI with confidence in a highly regulated environment.

Oncomine Assay Matches Standard Testing for Ovarian Cancer DNA Repair Deficiencies

https://bioengineer.org/oncomine-assay-matches-standard-testing-for-ovarian-cancer-dna-repair-deficiencies/
A new study found that the Oncomine Comprehensive Assay Plus (OCA Plus) effectively matches established companion diagnostics in identifying homologous recombination deficiency (HRD) in ovarian cancer samples, with an 86% overall concordance rate. This multi-gene platform can assess both molecular causes and genomic instability, potentially enabling decentralized HRD profiling and quicker diagnosis. While promising, the study's small cohort size and some diagnostic discrepancies highlight the need for larger, prospective studies to validate its routine clinical use and impact on treatment decisions.

Life Sciences and Laboratory Equipment Market Size, Share & Forecast 2036

https://www.factmr.com/report/life-sciences-and-laboratory-equipment-market
The Life Sciences and Laboratory Equipment Market is projected to reach USD 214.2 billion by 2036, growing at a CAGR of 6.9% from USD 109.9 billion in 2026. This growth is driven by expanding drug discovery, manufacturing investments by pharmaceutical companies, and increasing demand for analytical equipment and automated laboratory solutions. Key players are consolidating and integrating workflows to meet complex testing requirements and secure recurring revenue.

PR News | On the Move: Mars Snacking Names Belo Corp. Affairs Chief - Tue., Nov. 17, 2026

https://www.odwyerpr.com/story/public/25624/2026-11-17/move-mars-snacking-names-belo-corp-affairs-chief.html
This article details several significant personnel appointments in the public relations and marketing communications sector. Key moves include João Belo being named global VP of corporate affairs for Mars Snacking, Dave Anderson becoming CMO at BigPanda, Keith Schubert joining Rise and Shine and Partners as communication senior manager, and Tyler Holder becoming a shareholder at High Reason. The article also mentions other notable appointments at Teneo, INFINITE, Banc of California, and the PGA Tour.
Advertisement

How CO2 Purity Monitoring Supports Carbon Capture and Reuse

https://www.azocleantech.com/article.aspx?ArticleID=2202
This article discusses how CO2 purity monitoring systems, specifically Thermo Fisher Scientific's MAX-Bev system, are essential for the successful implementation of circular carbon capture and reuse by companies like CarbonQuest. The monitoring ensures that captured CO2 from sources like natural gas boiler exhausts meets the stringent purity standards required for commercial applications such as food and beverage. This process helps decarbonize buildings and industries while creating a valuable, locally sourced CO2 product.

Form 4 Thermo Fisher Scientific : Gianluca Pettiti (President & COO) For: 13 November

https://uk.investing.com/news/stock-market-news/form-4-thermo-fisher-scientific--gianluca-pettiti-president--coo-for-13-november-93CH-4986176
This article reports on a Form 4 filing for Thermo Fisher Scientific, detailing transactions made by Gianluca Pettiti, President & COO, on November 13. The piece highlights the company's stock symbol TMO and includes market data for various indices, commodities, and other stocks. It provides a brief update on insider trading activity at Thermo Fisher Scientific.

Form 4 Thermo Fisher Scientific : Gianluca Pettiti (President & COO) For: 13 November

https://ca.investing.com/news/stock-market-news/form-4-thermo-fisher-scientific--gianluca-pettiti-president--coo-for-13-november-93CH-4962272
This article reports on a Form 4 filing for Thermo Fisher Scientific, specifically detailing an insider transaction involving Gianluca Pettiti, the company's President & COO. The filing pertains to activity on November 13. The article provides the title of the filing and the key individual involved.

Thermo Fisher COO Gianluca Pettiti disposes of $2.9M in TMO stock

https://uk.investing.com/news/stock-market-news/thermo-fisher-coo-gianluca-pettiti-disposes-of-29m-in-tmo-stock-93CH-4986170
Gianluca Pettiti, COO of Thermo Fisher Scientific Inc. (NASDAQ:TMO), sold approximately $2.9 million worth of company stock on November 13, 2026, while also exercising stock options. The sale was executed under a Rule 10b5-1 trading plan and occurred as the stock traded near its 52-week high, appearing overvalued according to InvestingPro analysis. This insider transaction follows a period of strong financial performance for Thermo Fisher, including surpassing Q3 2026 earnings and revenue forecasts, and positive analyst revisions.

Thermo Fisher COO Gianluca Pettiti disposes of $2.9M in TMO stock

https://ca.investing.com/news/stock-market-news/thermo-fisher-coo-gianluca-pettiti-disposes-of-29m-in-tmo-stock-93CH-4962266
Gianluca Pettiti, President and Chief Operating Officer of Thermo Fisher Scientific Inc., sold approximately $2.9 million worth of TMO stock on November 13, 2026, while also exercising stock options. The sale was executed under a Rule 10b5-1 trading plan and occurred as the stock traded near its 52-week high, with InvestingPro analysis suggesting it is overvalued. Following these transactions, Pettiti directly holds 22,816.14 shares and 3,734 derivative securities.
Advertisement

Thermo Fisher Scientific Inc. stock falls Monday, still outperforms market

https://www.marketwatch.com/data-news/thermo-fisher-scientific-inc-stock-falls-monday-still-outperforms-market-4fa14622-3bb53c83904d
Shares of Thermo Fisher Scientific Inc. fell 1.27% on Monday, closing at $691.33, despite a broader market decline where the S&P 500 Index dropped 1.92% and the Dow Jones Industrial Average fell 1.41%. The company's stock is currently 4.98% below its 52-week high of $727.56, which was reached on November 11th.

Bruker Appoints Biopharma Entrepreneur and Immunology Leader Eicke Latz to Board

https://www.citybiz.co/article/933728/bruker-appoints-biopharma-entrepreneur-and-immunology-leader-eicke-latz-to-board/
Bruker Corporation has appointed Dr. Eicke Latz, a physician-scientist and biopharma entrepreneur specializing in immunology, to its Board of Directors, effective January 1, 2027. Dr. Latz brings extensive experience in academic research, biotechnology company formation, and drug development, particularly in innate immunity and inflammation. His appointment aims to enhance Bruker's expertise in disease biology and biopharmaceutical development as the company expands its life sciences and drug discovery technologies.

North America Bioprocessing Technology Market Companies, Size & Trends 2026-2035

https://www.precedenceresearch.com/north-america-bioprocessing-technology-market
The North America bioprocessing technology market, valued at USD 13.59 billion in 2026, is projected to reach USD 31.01 billion by 2035, growing at a CAGR of 9.60%. This growth is driven by expanding biologics pipelines, onshoring investments, CDMO expansion, and the scaling of cell and gene therapies. Key players include Thermo Fisher Scientific, Cytiva (Danaher), and Merck KGaA (MilliporeSigma), with consumables and single-use systems dominating the product segment and the U.S. leading the market regionally.

Amdocs (NASDAQ:DOX) Director Acquires $104,300.00 in Stock

https://www.marketbeat.com/instant-alerts/insider-amdocs-nasdaq-dox-director-acquires-10430000-in-stock-2026-11-16/
Amdocs Director Eliahu Meir Gelman recently purchased 2,500 shares of Amdocs (NASDAQ:DOX) for $104,300, increasing his direct holdings by 0.71%. This insider transaction occurred as the company reported quarterly earnings and revenue that matched analyst estimates, alongside a declared quarterly dividend of $0.569 per share. Despite mixed analyst ratings, the purchase may signal confidence in the company's future performance.

What Thermo Fisher Scientific Holders Bought Into

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/what-thermo-fisher-scientific-holders-bought-into
This article examines the investment narratives surrounding Thermo Fisher Scientific (NYSE:TMO) over the past year. It contrasts optimistic and cautious analyst views on the company's valuation, considering factors like aging populations, gene therapies, academic demand, and acquisition risks. The analysis reviews recent financial performance and how it aligns with these narratives, also touching on the impact of a planned microbiology unit divestiture.
Advertisement

Cape EMS firms up strategic life sciences engagement with US-based Thermo Fisher Scientific

https://focusmalaysia.my/cape-ems-firms-up-strategic-life-sciences-engagement-with-us-based-thermo-fisher-scientific/
Cape EMS Bhd has finalized a contract manufacturing agreement and an initial project addendum with Thermo Fisher Scientific, marking a significant step in its life sciences expansion strategy. The agreement, facilitated by Cape EMS's subsidiary iConn Technologies, involves R&D support and production across the US, Europe, and Asia, covering complex electromechanical assemblies and integrated systems. This collaboration aims to strengthen Malaysia's role in advanced life sciences manufacturing and contributes to Cape EMS's broader CEB 2.0 transformation.

Sequencing Consumables Market Forecast to 2035: Clinical NGS Adoption and Declining Costs to Drive Forward Growth

https://www.indexbox.io/blog/sequencing-consumables-market-forecast-to-2035-clinical-ngs-adoption-and-declining-costs-to-drive-forward-growth/
The global sequencing consumables market is predicted to experience sustained expansion, with a CAGR of 12.5% from 2026 to 2035, driven primarily by the accelerating adoption of next-generation sequencing (NGS) in clinical diagnostics and ongoing reductions in sequencing costs. Asia-Pacific is expected to lead regional growth, while clinical diagnostics and genetic testing will remain the largest and fastest-growing end-use sector. Key players include Illumina, Thermo Fisher Scientific, and Pacific Biosciences, among others.

Form 144 THERMO FISHER SCIENTIFIC INC. For: 14 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-thermo-fisher-scientific-inc-for-14-november-93CH-4982713
This article from Investing.com announces the filing of Form 144 by Thermo Fisher Scientific Inc. on November 14. Form 144 typically relates to the intent to sell restricted or control securities. The brief notice provides no further details on the nature or volume of the transaction.

Form 144 THERMO FISHER SCIENTIFIC INC. For: 14 November By Investing.com

https://au.investing.com/news/stock-market-news/form-144-thermo-fisher-scientific-inc-for-14-november-93CH-4771188
This article announces the filing of Form 144 for Thermo Fisher Scientific Inc. on November 14. The content is a brief financial market update from Investing.com, typical for regulatory filings notifications.

QNTM: Quantum BioPharma equity rises 91% to $9.77M in Q3 2026

https://www.quantisnow.com/insight/sec-form-6-k-filed-by-quantum-biopharma-ltd-6789320
Quantum BioPharma (QNTM) reported a 91% increase in shareholders' equity to $9.77 million in Q3 2026, alongside a 24% year-over-year reduction in operating expenses. The company also signed a Study Start-Up Agreement with Thermo Fisher Scientific for its Lucid-MS Phase 2 trial after receiving FDA IND clearance. These developments highlight a stronger balance sheet and progress in its clinical pipeline.
Advertisement

A live webcast will carry Thermo Fisher CEO Marc Casper's UBS chat Nov. 19.

https://www.stocktitan.net/news/TMO/thermo-fisher-scientific-to-participate-in-ubs-2026-ceo-call-series-2hisqeej5vzc.html
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its CEO, Marc N. Casper, will participate in a fireside chat hosted by UBS on November 19, 2026, at 8:30 a.m. ET. A live webcast of the presentation will be available via the Investors section of the company's website. The company, a global leader in serving science with over $45 billion in annual revenue, aims to enable its customers to make the world healthier, cleaner, and safer.

Gianluca Pettiti proposes selling 4,133 Thermo Fisher (TMO) shares.

https://www.stocktitan.net/sec-filings/TMO/144-thermo-fisher-scientific-inc-sec-filing-59511df44b69.html
Gianluca Pettiti, an officer at Thermo Fisher Scientific Inc. (TMO), has proposed selling 4,133 common shares with an aggregate market value of approximately $2.9 million, slated for November 13, 2026. The filing also notes a concurrent 3,733-share stock-option exercise for cash on the same date. Pettiti previously sold 4,133 common shares on August 31, 2026, for over $2.5 million.

Thermo Fisher Scientific (TMO) Dividend And Bond Moves Leave Valuation Questions Open

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-dividend-and-bond-moves-leave-v
Thermo Fisher Scientific (TMO) has announced a quarterly cash dividend of $0.47 per share and completed new Swiss franc bond offerings, providing investors with insight into its shareholder returns and funding strategy. While the stock has seen significant gains recently, analyst consensus views it as fairly valued at $750.92, whereas a DCF model suggests it might be overvalued at its current price of $699.44. These mixed signals, combined with an upcoming executive retirement, create valuation questions for investors.

What Could Guardant Health (GH) New Cancer Test Tools Mean For Oncologists?

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/what-could-guardant-health-gh-new-cancer-test-tools-mean-for
Guardant Health (GH) has launched five new epigenomic applications for its Guardant360 Liquid test, specifically targeting breast and lung cancers. These tools, powered by the InfinityAI platform, aim to assist oncologists in selecting therapies for patients whose tumors lack clear genomic biomarkers. This expansion is expected to broaden the clinical utility and addressable market for Guardant360 Liquid testing, reinforcing the company's "multi omics data and InfinityAI" growth narrative.

Is Bio Techne (TECH) Fully Valued On Its Latest Earnings And Merck Linked Dividend?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tech/bio-techne/news/is-bio-techne-tech-fully-valued-on-its-latest-earnings-and-m
Bio-Techne (TECH) recently reported first-quarter results with sales of US$299.71 million and net income of US$28.29 million, along with a US$0.08 quarterly dividend related to its Merck KGaA transaction. The stock has seen significant year-to-date and annual returns, but Simply Wall St's analyst consensus suggests it is modestly overvalued with a fair value estimate of $70.73 compared to its recent close of $72.84. Investors are weighing the softer quarterly earnings against steady sales and the potential benefits of the Merck deal and recurring revenue from consumables.
Advertisement

Thermo Fisher Introduces Benchtop Spark-OES Analyzer for Routine Metals Quality Control

https://www.spectroscopyonline.com/view/thermo-fisher-introduces-benchtop-spark-oes-analyzer-for-routine-metals-quality-control
Thermo Fisher Scientific has launched the ARL Spark Companion OES Metal Analyzer, a benchtop spark optical emission spectrometry system designed for routine metal composition analysis and quality control. This new instrument aims to enable faster, in-house alloy verification closer to production environments, serving as either a standalone unit or a complementary/backup system to larger spectrometers. It utilizes a multi-optics CMOS detector in a vacuum environment, supporting elemental analysis including carbon, phosphorus, and sulfur in steel, and comes with factory-calibrated methods for various alloys.

Supreme Court Hears Oral Arguments in Anderson v. Intel Corp. Investment Policy Committee

https://www.lawyersandsettlements.com/legal-news/erisa/supreme-court-hears-oral-arguments-in-anderson-v-intel-corp-inve-24508.html
The Supreme Court heard oral arguments in Anderson v. Intel Corp. Investment Policy Committee, an ERISA class action challenging Intel's investment of 401(k) assets in private equity and hedge funds. The case revolves around whether plaintiffs must provide a "meaningful benchmark" for comparison when alleging imprudent investment choices, particularly given the opaque nature of these alternative investments. The outcome could significantly impact how retirement plan participants protect and direct their retirement savings.

Thermo Fisher Scientific Continues Semiconductor Lab-to-Fab Innovation with Multiple Installations of Optis™ FIB-SEM

https://www.azom.com/news.aspx?newsID=66039
Thermo Fisher Scientific has announced multiple installations of its Optis™ focused ion beam-scanning electron microscope (FIB-SEM) to advance semiconductor manufacturing. This system automates sample preparation, robotics, and AI-enabled tools to provide faster, more accurate data for chip development. By streamlining workflows and preparing samples directly from wafers for transmission electron microscopy, Optis FIB-SEM helps chipmakers make more informed decisions and meet the demands of increasingly complex device scaling.

Thermo Fisher Scientific Continues Semiconductor Lab-to-Fab Innovation with Multiple Installations of Optis™ FIB-SEM

https://www.biospace.com/press-releases/thermo-fisher-scientific-continues-semiconductor-lab-to-fab-innovation-with-multiple-installations-of-optis-fib-sem
Thermo Fisher Scientific has announced multiple installations of its Optis™ FIB-SEM system, designed to enhance semiconductor manufacturing. This system integrates automated sample preparation, robotics, and AI to provide faster, more accurate, and consistent data for chip development. Optis FIB-SEM streamlines workflows for advanced logic and memory devices by preparing samples directly from wafers, significantly reducing manual steps and improving data quality for transmission electron microscopy (TEM).

Nuclear Medicine’s Next Era: Preparing Medtech for the Rise of Precision Therapies

https://www.mpo-mag.com/exclusives/nuclear-medicines-next-era-preparing-medtech-for-the-rise-of-precision-therapies/
Nuclear medicine is entering a new era driven by advances in radiopharmaceuticals, imaging technologies, and theranostics, creating a convergence that reshapes disease detection and treatment. While innovation in precision radiopharmaceuticals is accelerating, the healthcare ecosystem, including medtech infrastructure, is struggling to keep pace, risking suboptimal utilization and limited patient access. Addressing this requires a holistic approach focused on adaptable hardware, quantitative software, integrated workflows, and reliable access to radiopharmaceuticals, demanding collaboration across all stakeholders to scale precision care effectively.
Advertisement

Thermo Fisher Scientific stock reaches all-time high at 724.07 USD

https://ca.investing.com/news/stock-market-news/thermo-fisher-scientific-stock-reaches-alltime-high-at-72407-usd-93CH-4950368
Thermo Fisher Scientific (TMO) stock has achieved an all-time high of $724.07, representing a 22.14% increase over the past year and a 59% gain in the last six months. Despite this, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. The company recently reported strong Q3 2026 financial results with adjusted EPS of $6.68 and revenue of $12.14 billion, leading several analysts to reiterate Buy ratings and raise price targets.

Thermo Fisher Scientific ARL Spark Companion OES Metal Analyzer

https://www.qualitymag.com/articles/100065-thermo-fisher-scientific-arl-spark-companion-oes-metal-analyzer
Thermo Fisher Scientific has launched the ARL Spark Companion OES Metal Analyzer, a new benchtop spark optical emission spectrometry system designed for reliable routine metal composition analysis and timely quality control. This analyzer offers a multi-optics CMOS detector system and a compact multi-frequency spark source, providing analytical performance with an intuitive Spark Navigator workflow for quick analysis. It is suitable for various applications, including foundries, metal processing, recycling, and final product quality control across different metal types.

Thermo Fisher Scientific stock reaches all-time high at 724.07 USD

https://www.investing.com/news/company-news/thermo-fisher-scientific-stock-reaches-alltime-high-at-72407-usd-93CH-5019232
Thermo Fisher Scientific (TMO) stock has hit an all-time high of $724.07, demonstrating a significant 22.14% increase over the past year and a 59% gain in the last six months. Despite an InvestingPro analysis suggesting the stock might be overvalued, the company reported robust Q3 2026 financial results with adjusted EPS and revenue surpassing estimates, leading to raised full-year guidance and reiterated Buy ratings from analysts like UBS and Argus.

Is Bruker (BRKR) A Bargain Following Reaffirmed Outlook And Mixed Q3 Results?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-bruker-brkr-a-bargain-following-reaffirmed-outlook-and-mi
Bruker (BRKR) recently released mixed Q3 2026 results, including higher sales but also a larger goodwill impairment charge and a wider loss, while reaffirming its full-year outlook. Despite a recent share price decline, the stock has shown positive momentum over the past month and year-to-date. Analysts currently view Bruker as slightly undervalued, with a fair value of approximately $63.83.

Guardant Health adds five epigenomic cancer-testing tools

https://mugglehead.com/guardant-health-epigenomic-applications-cancer-treatment-selection/
Guardant Health has expanded its Guardant360 Liquid blood test with five new epigenomic applications designed to improve breast and lung cancer treatment selection. These additions use the company's InfinityAI platform to combine genomic and epigenomic signals, aiming to inform therapy choices when conventional mutation markers are insufficient. The company reported $231.3 million in third-quarter revenue, with oncology test volume up 58 percent year-over-year.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement